Irinotecan Hydrochloride

• Safety, tolerability, and efficacy of mFOLFIRINOX ±BNT321 as adjuvant therapy following curative resection in patients with pancreatic adeno… Not authorised
  2023-506014-47-00 Phase I/II 4 countries BioNTech SE
• PRODIGE 113 (FFCD 2314) – REWENEC – 01 STUDY Randomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic co… Not authorised
  2024-519922-19-00 Phase II 1 country Hospices Civils De Lyon
• Impact of Biweekly and Triweekly Dosing Regimens Pending
  2025-522305-38-00 Phase II 1 country University Of Pecs
• Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma Recruiting
  2024-516233-12-00 Phase I (Other) 2 countries Asociacion Grupo Tratamiento De Tumores Digestivos
• Phase Ib-II, non-randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with modFOLFIRINOX for front-line trea… Recruiting
  2024-511459-16-00 Phase I/II 1 country Clinica Universidad De Navarra
• Using lab-grown mini-tumors from pancreatic cancer tissue to predict and improve post-surgery treatment for pancreatic cancer Recruiting
  2023-510490-34-00 Phase II 1 country Universitaetsklinikum Ulm AöR
• A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma Recruiting
  2024-514635-26-00 Phase III 1 country Medical University Of Gdansk
• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph… Recruiting
  2023-509630-19-00 Phase III 11 countries Daiichi Sankyo Inc.
• A clinical study to assess the safety and efficacy of oral ART0380 as a single agent or in combination in solid tumors Recruiting
  2024-511534-12-00 Phase I (FiH) 2 countries Artios Pharma Limited
• Gemcitabine plus nab-PAclitaxel as switch maiNTEnance versus cONtinuation of modified FOLFIRINOX as first-line chemotherapy in patients with… Recruiting
  2024-515214-41-00 Phase III 1 country Fondazione GONO G.I.
• REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemoth… Recruiting
  2024-516709-22-00 Phase II/III 1 country Centre Hospitalier Regional Universitaire
• Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting
  2024-517863-22-00 Phase III 1 country Azienda USL IRCCS Di Reggio Emilia
• PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRES… Recruiting
  2023-506632-32-00 Phase III 1 country Fondazione GONO G.I.
• EFFIPEC Recruiting
  2024-516224-34-00 Phase III 1 country Uppsala University
• A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch… Recruiting
  2023-505660-11-00 Phase III 8 countries Transthera Sciences (Nanjing) Inc.
• Study of Combination Therapies in Esophageal Cancer Recruiting
  2023-505189-26-00 Phase I/II 3 countries Merck Sharp & Dohme LLC
• A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or … Recruiting
  2023-506517-22-00 Phase I/II 4 countries Janssen - Cilag International
• Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minima… Recruiting
  2024-515681-14-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
• Study evaluating the tailored management of locally-advanced rectal carcinoma Recruiting
  2024-511609-44-00 Phase II/III 1 country Institut Regional Du Cancer De Montpellier
• OPTIMISE Recruiting
  2023-509814-12-00 Phase II 3 countries Region Midtjylland
• Non inferiority study of preoperative chemotherapy without pelvic irradiation for rectal cancer Recruiting
  2024-510580-28-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Nordic Pancreatic Cancer Trial (NORPACT) – 1 Recruiting
  2024-517719-65-00 Phase II 2 countries Oslo University Hospital HF
• Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC Ended
  2024-516063-89-00 Phase III 4 countries Revolution Medicines Inc.
• A clinical study of MK-2870 in people with stomach cancer (MK-2870-015) Ended
  2023-505423-31-00 Phase III 7 countries Merck Sharp & Dohme LLC

Showing 1–24 of 33 trials